… acid–DPhe1-Tyr3-octreotate (DOTATATE) PET/CT, a functional imaging modality for
assessment of well-differentiated neuroendocrine tumors (NETs). It has become the preferred …

Somatostatin receptor (SSTR) imaging is widely used for guiding the management of
neuroendocrine tumor (NET) patients. Ga-DOTATATE approval by the US Food and Drug …

… providers use SSTR PET/MRI as an alternative to a combination of SSTR PET/CT and
contrast-enhanced CT of the chest, abdomen (biphasic liver protocol), and pelvis. SSTR PET/MRI …

… the literature to assess the role of 68 Ga PET imaging in neuroendocrine tumors (NETs). …
The role of 68 Ga-DOTATATE PET in patients with neuroendocrine tumors and negative or …

… 68 Ga-DOTATATE) PET/CT in patients who are suspected of having a NET (17), such that
it is now recommended by the guidelines of the European Neuroendocrine Tumor Society (6). …

… (white arrow), none of the tumor manifestations are revealed by CXCR4-directed PET imaging.
Incidental finding: The mediastinal tracer uptake in 68 Ga-Pentixafor PET (white star) was …

… PET radiopharmaceuticals can be directed toward assessing receptor expression or
characterizing the intratumoral metabolic processes. The metabolic events and receptor targets that …

… of the neuroendocrine phenotype, … PET has excellent diagnostic performance in patients
with low-grade midgut NETs [22]. In this clinical setting, 18 F-DOPA PET is indicated for tumor …

… Somatostatin receptor (SSTR) PET has demonstrated a significant improvement over
conventional imaging (CI) in patients with neuroendocrine tumors (NETs). SSTR PET should …

… DOTATATE PET in patients with neuroendocrine tumors and … and G3 tumors, the need for
non–SSTR-based PET imaging … to imaging with [ 18 F]FDG PET/CT, as the increased cellular …